Sanoptis ha diffuso questo post
Sanoptis is proud to announce a strategic investment in Retinai, strengthening our mission to advance ophthalmic care through cutting-edge technology. This investment supports the integration of RetinAI’s innovative AI solutions, including the RetinAI Discovery® platform, to enhance data-driven insights and improving diagnostic accuracy across our clinics in Europe. 🌍 Dr. Volker Wendel, CEO of Sanoptis, shares: “We are thrilled to enter into this partnership with Ikerian and RetinAI which will enable us to drive significant improvements in ophthalmology clinical practice. Together, we will focus on advancing technologies that empower clinicians, enhance workflow efficiency and importantly, improve patient outcomes. This partnership marks a major step forward in transforming clinical practice for the better.” 🗞 ➡ Read the full Press Release here: https://lnkd.in/ei8x7-w6 Together, we’re shaping the future of ophthalmology! 👁️💡